Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: A multicenter randomized clinical trial

Cancer

Volumn 78, Issue 1, 1996, Pages 63-69

  Ianniello, Giovanni P ^a   De Cataldis, Giuseppe ^b   Comella, Pasquale ^c   Scarpati, Michele Della Vittoria ^d   Maiorino, Alfonso ^e   Brancaccio, Luigi ^e   Cioffi, Riccardo ^f   Lombardi, Alessandra ^a   Carnicelli, Pietro ^b   Tinessa, Vincenza ^a  

^a G RUMMO HOSPITAL   (Italy)

^b Ospedale G da Procida   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e MONALDI HOSPITAL   (Italy)

^f City Hospital   (Italy)

Author keywords

cisplatin epirubicin vindesine regimen; Ionidamine; nonsmall call lung carcinoma; toxicity

Indexed keywords

CISPLATIN; EPIRUBICIN; LONIDAMINE; VINDESINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; WORLD HEALTH ORGANIZATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; HUMANS; INDAZOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; VINDESINE;

EID: 8944237973     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960701)78:1<63::AID-CNCR11>3.0.CO;2-5     Document Type: Article

References (48)

1. La Vecchia C, Lucchini F, Negri E, Boyle P, Maisonneuve P, Levi F. Trends of cancer mortality in Europe, 1955-1989: II: respiratory tract, bone, connective and soft tissue sarcomas, and skin. Eur J Cancer 1992;28:514-9.
2. Stjernsward J, Stanley K. Lung cancer: a world-wide health problem. Lung Cancer 1988;4:1-2.
3. Faulds D. Current options in the treatment of non-small cell lung cancer. Drugs 1992;44:46-59.
4. Miller TP. Rationale for the use of chemotherapy in non-small-cell lung cancer. Semin Oncol 1990;17:11-3.
5. Haskell CM. Chemotherapy and survival of patients with non-small cell lung cancer: a contrary view. Chest 1991; 99:1325-6.
6. Vokes EE, Bitran JD, Vogelzang NJ. Chemotherapy for non-small-cell lung cancer: the continuing challenge. Chest 1991;99:1326-8.
7. Buccheri GF. Chemotherapy and survival in non-small-cell lung cancer: the old vexata question. Chest 1991;99:1328-9.
8. Cellerino R, Tummarello D, Guidi F, Isidori P, Raspugli M, Biscottini B, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991;9:1453-61.
9. Green MR. New directions for chemotherapy in non-small-cell lung cancer. Chest 1993;103:370-2.
10. Cullen MH. Trials of radical radiotherapy versus chemotherapy plus radical radiotherapy in non-small-cell lung cancer. Semin Oncol 1994;21:34-41.
11. Gralla RJ, Casper ES, Kelsen DP, Braun Jr DW, Dukeman NE, Martini N, et al. Cisplatinum and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 1981;95:414-20.
12. Klastersky J. VP-16 and cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 1985;12:17-20.
13. Kris MG, Gralla RJ, Wertheim MS. Trial of the combination of mitomycin, vindesine and cisplatin in patients with advanced non-small-cell lung cancer. Cancer Treat Rep 1986; 70:1091-6.
14. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, et al. Polychemotherapy in advanced non-small-cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
15. Hopwood P, Thatcher N. Preliminary experience with quality of life evaluation in patients with lung cancer. Oncology 1990;4:158-62.
16. Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C. Lonidamine: a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst 1981; 66:497-9.
17. Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B, et al. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 1981;41: 4661-6.
18. De Martino C, Malorni W, Accinni L, Rosati F, Nista A, Formisano G, et al. Cell membrane changes induced by lonidamine in human erythrocytes and T-lymphocytes, and Ehrlich ascites tumor cells. Exp Mol Pathol 1987;46:15-30.
19. Forster R, Campana A, D'Onofrio E, Henderson L, Mosesso P, Scorza Barcellona P. Lonidamine: a non-mutagenic antitumor agent. Carcinogenesis 1990;11:1509-15.
20. Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei III E. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother Pharmacol 1989;25:32-6.
21. Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu S, Frei III E. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Cancer Res 1991;51:780-4.
22. Raaphorst GP, Ko D, Feeley MM, Danjoux CE, Maroun J, Evans WK. The effect of lonidamine alone and in combination with cisplatin on in vitro growth and viability of lung squamous cell carcinoma cell lines. Anticancer Res 1991;11:41-8.
23. Bellelli A, Bellelli L, Di Palma M, Lorenzon I, Mattioni M, Nista A, et al. Effects of VM26 and lonidamine on a B 16 melanoma cell line. Anticancer Res 1990;10:565-78.
24. Villa R, Zaffaroni N, Orlandi L, Bearzotto A, Costa A, Silvestrini R. In vitro effect of lonidamine on the cytotoxicity of mitomycin-C and BCNU in human colon adenocarcinoma cells. Eur J Cancer 1994;30:1534-40.
25. Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 1992;52:813-17.
26. Del Bufalo D, Zupi G. In vitro potentiation of epirubicin activity by lonidamine in a human breast cancer cell line. Int J Oncol 1994;4:737-40.
27. Savini S, Zoli W, Nanni O, Volpi A, Frassineti GL, Magni E, et al. In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. Breast Cancer Res Treat 1992;24:27-34.
28. Zupi G, Greco C, Laudonio N, Benassi M, Silvestrini B, Caputo A. In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin. Anticancer Res 1986;6:1245-50.
29. Robustelli della Cuna G, Pedrazzoli P. Toxicity and clinical tolerance of lonidamine. Semin Oncol 1991;48:18-22.
30. Neri B, Lottini G, Bandinelli E, Cini-Neri G. Doxorubicin plus lonidamine: in vivo metabolic effects on the rat heart. Anticancer Drugs 1991;2:401-4.
31. Ianniello GP, Zotti F, Ruggiero A, Crafa F. Enhancement of CEV combination in advanced NSCLC by Lonidamine. A pilot study. 15th International Cancer Congress, Hamburg, August 16-22, 1990:119.
32. World Health Organization. Histology typing of lung tumors. Am J Clin Pathol 1982;777:26-31.
33. International Union Against Cancer. TNM classification of malignant tumors. 4th edition. Geneva: UICC, 1987:69-73.
34. World Health Organization. WHO Handbook for reporting the results of cancer treatment. WHO offset Pub. No 48. Geneva: WHO, 1979.
35. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
36. BMDP. Statistical software manual. Berkeley: University of California Press, 1985:557-94.
37. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;135:185-98.
38. Bellamy WT, Dalton WS, Dorr RT. The clinical relevance of multidrug resistance. Cancer Invest 1990;8(5):547-62.
39. Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal foundation award lecture. Cancer Res 1993;53:747-54.
40. Calabresi F. Drug resistance lonidamine. Prin Pract Oncol Updates 1994;8(6):1-15.
41. Citro G, Cucco C, Verdina A, Zupi G. Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. Br J Cancer 1991;64:534-6.
42. Tomirotti M, Bernardo G, Epifani C, Biasioli R, Franchi R, Mensi F, et al. Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients. Int J Oncol 1993;3:213-7.
43. De Lena M, De Mitrio A, Catino A, Lorusso V, Brandi M. Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results. Int J Oncol 1994;4:779-82.
44. Gadducci A, Brunetti I, Muttini MP, Fanucchi A, Dargenio F, Giannessi PG, et al. Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. Eur J Cancer 1994;10:1432-5.
45. Iaffaioli RV, Tortoriello A, Facchini G, Caponigro F, Mastrantonio F, Barzelloni ML, et al. Recovery of sensitivity to cis-platinum and epidoxorubicin by lonidamine and interferon in advanced ovarian cancer. Int J Oncol 1994;4:1265-9.
46. Gatzemeir V, Cavalli F, Häußinger K, Kaukel E, Koschel G, Martinelli G, et al. Phase III trial with and without lonidamine in non small cell lung cancer. Semin Oncol 1991;18(Suppl 4):42-8.
47. Buccheri GF, Ferrigno D, for the Cuneo Lung Cancer Study Group. A randomized trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Eur J Cancer 1994;10:1424-31.
48. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients fron 52 randomised clinical trials. BMJ 1995;311:899-909.